Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2000

View Archived Issues

Combination metformin/rosiglitazone effective in type II diabetes

Sertraline efficacious in treating posttraumatic stress disorder

Ciba Vision to market Salagen Tablets in Europe

Protarga enters CRADA with NCI for novel anticancer therapies

AuRx's HSV-2 theracine cleared for clinical trials in Mexico

Axcan to acquire Photofrin rights

SmithKline Beecham seeks marketing clearance for Paxil in GAD

Zyban approved in E.U. for smoking cessation

TANGO-191 and TANGO-195: new transmembrane proteins discovered by Millennium

Celltech dedicates significant resources to study of integrin inhibitors

Pfizer's new CETP inhibitors claimed for atherosclerosis and associated conditions

Selective thrombin inhibitors described in recent patent by Merck researchers

New MMP inhibitors under study at Ishihara Sangyo as antitumor and antiarthritic agents

Widely used anesthetic greatly reduces pain during rectal prostate biopsy

Maxamine plus IL-2 improves survival in late-stage malignant melanoma

Once-daily Detrol shows significant efficacy, good safety in large study in overactive bladder

Anti-HHV-6 activity of CMV-423 reported at Antiviral Research conference

Novel immune stimulant may improve HBV vaccine

AUA news: preclinical profile of new alpha1A/D blocker with enhanced uroselectivity

Gliatech submits ADCON-P preclinical module to FDA

AN-238: a novel receptor-targeted therapy for prostate cancer

Genome Therapeutics and Schering-Plough extend asthma agreement

La Jolla to conduct phase III trial of lupus drug candidate

GI-198745 suitable for combination with tamsulosin or terazosin according to recent clinical data

Humalog use expanded to new patients

Laboratory findings support greater utility of two Bayer compounds for CMV versus ganciclovir

NCI awards grant to SuperGen for radiation-sensitizing agent

Approval of new indications for ACE inhibitor recommended by FDA advisory panel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...